Contraline Announces 24-Month Safety and Efficacy Results from First-in-Human Trial of ADAM™
Contraline, a clinical-stage male contraception company, today announced that participants in the First-in-Human clinical trial of ADAM™ (“The ADAM Study”) have reached a critical milestone, demonstrating both safety and efficacy at the 24-month mark.